מגאקסין IV - Megaxin iv
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | J01MA Fluoroquinolones |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | ת×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Megaxin IV is indicated for the treatment of adults (> 18 years of age) with Community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and Complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with Megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×××קס×× IV ××××ר ××©×¨× ××ר×××ת
×××קס×× IV ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BAYER PHARMA AG, GERMANY |
| ×©× ××¢× ×ר×ש×× | BAYER ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 5/2002. ר×ש××× ×ת×ר××: 11/2012 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
השינוי האחרון נעשה בֹ־17 במרץ 2014 ב־07:22